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Abstract 
 
Allograft outcome depends on a range of factors, including donor age, the allo-
immune response, ischemia-reperfusion injury, and interstitial fibrosis of the 
allograft. Changes in the epigenome, and in DNA methylation in particular, have 
been implicated in each of these processes, either in the kidney or other organ 
systems. This review provides a primer for DNA methylation analyses and a 
discussion on strengths and weaknesses of current studies, but also a 
perspective for future DNA methylation research in kidney transplantation. We 
present exciting prospects for leveraging DNA methylation analyses as a tool in 
kidney biology research, and as a diagnostic or prognostic marker for predicting 
allograft quality and success. Topics discussed include DNA methylation 
changes in aging, and in response to hypoxia and oxidative stress upon 
ischemia-reperfusion injury. Moreover, emerging evidence suggests that DNA 
methylation contributes to organ fibrosis and that systemic DNA methylation 
alterations correlate with the rate of kidney function decline in patients with 
chronic kidney disease and end-stage renal failure. Monitoring or targeting the 
epigenome could therefore reveal novel therapeutic approaches in 
transplantation and open up paths to biomarker discovery and targeted therapy. 
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Main Body Text 
Epigenetics involves the potentially stable and, ideally, inheritable mechanisms 
that control gene expression and that occur without changes in the DNA 
sequence(1). They can be generally grouped into three main categories: 
methylation of DNA, modifications of histones and changes in the positioning of 
nucleosomes(2). The interactions between these different epigenetic 
modifications determine their effect on gene expression and are fundamental to 
the regulation of many cellular processes. Epigenetic changes are often triggered 
by developmental, environmental or pathogenic stimuli and, because of their 
stability and heritability, can produce long-lasting cellular phenotypes(2). As 
such, they provide an interface between the environment and gene 
expression(1). In recent years, we have witnessed a growing interest in 
epigenetic research in various research domains, such as cancer or auto-
immunity. Also in the field of nephrology, interest has steadily been growing. 
However, so far, only few studies have focused on the role of epigenetic changes 
in kidney transplantation. This is somewhat surprising, as many key factors that 
influence DNA methylation, which is the best characterized epigenetic mark, are 
of major prognostic significance in kidney transplantation. Indeed, advanced 
donor age, alloreactive immune responses, ischemia-reperfusion injury and 
fibrosis significantly contribute to allograft survival and at the same time these 
factors also trigger DNA methylation changes.  
Therefore, this review aims to provide a perspective on the emerging role of DNA 
methylation in kidney transplantation. By pointing out major discoveries in related 
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research fields, we aim to highlight how epigenetic research can provide novel 
insights into the mechanisms of kidney transplant failure, and may thus 
contribute to improving long-term allograft survival.  
 
An introduction to DNA methylation and demethylation 
DNA methylation occurs almost exclusively at cytosines located in the context of 
a CpG dinucleotide(3). Although CpG dinucleotides are rare in the genome, a 
small fraction is clustered into so-called “CpG islands”. CpG islands have a high 
CpG density, are unmethylated under normal conditions and mostly co-localize 
with promoter regions in the genome(4, 5)(Figure 1). Methylation of CpG islands 
in promoters represses gene expression, by displacing transcription factors and 
attracting methyl-binding proteins that trigger gene silencing(6). DNA methylation 
leading to gene silencing is essential for dosage compensation in chromosome 
X-inactivation, for parent-of-origin-dependent imprinting, and more generally for 
cell differentiation and mammalian development(2) and has a major role in long-
term gene expression silencing. In the CpG context, with methylation on both 
DNA strands mirroring each other, DNA methylation patterns can be faithfully 
copied upon DNA replication, and transmitted to both daughter cells. As a 
consequence, DNA methylation patterns are stable, unless when they are 
actively altered. Such alterations occur extensively during development, and 
DNA methylation patterns are therefore cell-type and lineage specific. It thus 
endows unique functions to different cells and tissues that have identical 
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genomes(7-9). For instance, the DNA methylome of the kidney closely resembles 
the DNA methylome of other mesoderm-derived tissues(7). In addition, genes 
encoding kidney-specific transporters are hypomethylated in the rodent kidney 
compared to other organs(10). When specifically focusing on rodent proximal 
tubular cells, again genes that were hypomethylated compared to the kidney in 
general included those that were essential for proximal tubular cellular 
function(11). 
 
DNA methylation is maintained during cell division by the action of DNA 
methyltransferase 1 (DNMT1)(2). Recruted together with other components of 
the DNA replication machinery during the S-phase, DNMT1 binds to 
hemimethylated CpG sites and methylates the CpG on the newly synthesized 
unmethylated daughter strand, thus propagating methylation patterns and 
ensuring the stability of the epigenetic code. On the other hand, de novo 
methylation is orchestrated predominantly by the action of DNMT3a and 
DNMT3b(2). These methyltransferases are capable of methylating unmodified 
CpG sites. De novo methylation primarily occurs during embryogenesis at the 
majority of CpG sites in the genome to establish the basal pattern of DNA 
methylation, and subsequently targeted during early development to repress 
genes involved in pluripotency(12). Following differentiation, cells lose their de 
novo methylation activity and their DNA methylome is further maintained during 
cell replication through DNMT1 activity. Still, DNMT3a and DNMT3b are 
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ubiquitously expressed at low levels in adult tissues, and certain circumstances 
can trigger de novo methylation of genes(12). 
 
 
The reverse process, DNA demethylation, was initially thought to occur 
passively. Recent evidence however identified active demethylation through the 
ten-eleven translocation methylcytosine dioxygenases (TET1, TET2 or TET3). 
These enzymes oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine 
(5hmC)(13), leading to DNA demethylation(14)(Figure 1). Global erasure of the 
methylome occurs at specific stages of mammalian development(15). However, 
TET proteins are also ubiquitously expressed at varying degrees in non-dividing 
somatic cells, and active DNA demethylation can occur in most cell types (3).  
 
Some studies suggest that 5hmC is more than an intermediate to demethylation, 
having the potential to act as a bona fide epigenetic mark in its own right(16). In 
highly expressed genes, 5hmC levels are low around the transcription start site 
and increase towards the 3’ end of the gene(16). Moreover, hydroxymethylation 
is a stable DNA modification and tissues with differentiated, non-proliferating cell 
types have a higher 5hmC content(17). This is particularly true for the brain, but 
also in the kidney 5hmC levels are relatively abundant(17). 
 
A comprehensive picture of the regulation of DNA methylation turnover is 
currently lacking(3). Still, it is evident that it is the interaction between different 
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epigenetic players that ultimately determines gene expression. For example, the 
effect of DNMTs on DNA methylation is influenced by their interaction with 
histones and nucleosomes, while on the other hand DNA methylation can also 
mediate histone and nucleosome modifications(2). In addition, genetic variability 
is an important determinant of the DNA methylation profile, probably mediated 
through variability in transcription factor binding, another factor influencing DNA 
methylation(3). Finally, also environmental stimuli can influence DNA 
methylation(1). In this review, we will additionally focus on factors that are 
relevant for transplantation research.   
 
We will now discuss how the major prognostic factors determining survival of 
kidney transplants are known to have a profound impact on DNA methylation. As 
such, there might be unanticipated roles for DNA methylation in determining the 
long-term outcome. 
 
DNA methylation and cellular aging 
Advanced donor age is one of the key variables determining worse long-term 
outcome of kidney transplantation(18). Several underlying mechanisms have 
been proposed, including telomere shortening, accumulation of somatic 
mutations and oxidative stress, although their exact causality remains 
unclear(19). Only recently, epigenetic changes accumulating during cellular 
senescence have been detected. Indeed, with advanced age the variability in 
DNA methylation patterns increases significantly, a process referred to as 
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epigenetic drift(20). This increase in interindividual variability with advancing age 
is accompanied by an increase in methylation at sites with low methylation levels, 
such as CpG islands in promoters, and a decrease at sites with high methylation 
levels, such as nonisland CpGs(21).  
Interestingly, the link between age and DNA methylation is robust and does not 
seem to depend on the micro-environment, as one year after allogeneic 
hematopoietic stem cell transplantation, DNA methylation in peripheral blood 
cells, which originate from the donor stem cells, still correlates with donor age but 
not with recipient age(22). It has furthermore been suggested that aging affects 
the epigenome in a tissue-specific manner. For instance, the promoter of N-
cadherin, a cell adhesion molecule essential for cell polarity and thus renal 
function, is strongly methylated in aged, but not young, murine kidneys, which 
explains the age-dependent decrease in renal N-cadherin expression. Neither 
young or old rat livers display such a change in methylation or gene expression 
profile(23).  
Besides the increased variability in DNA methylation with age, the methylation 
state at certain CpGs are highly correlated with age, to the extent that they can 
be used to accurately predict chronological age(21). This process is referred to 
as the epigenetic clock. In this respect, a multi-tissue predictor of age was 
recently built by comprehensive analysis of publicly available DNA methylation 
data of 8000 samples encompassing 51 healthy tissues and cell types, including 
the kidney. At 353 CpGs across tissues, the methylation state predicted age(24). 
This illustrates that DNA methylation changes capture biological age, similar to 
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telomere shortening. In addition, the deviations of the age estimated by DNA 
methylation analysis from the chronological age independently associated with 
increased mortality, suggesting that methylation-based age can provide an better 
estimate of future lifespan than chronological age(25). Unfortunately, very little is 
known about age-related changes in the DNA methylome of the kidney. 
Moreover, the function of these epigenetic changes with age and the underlying 
mechanisms driving them are currently unknown(21). The role of epigenetic 
dysregulation in allografts from older donors thus warrants additional 
investigation. 
 
DNA methylation and the immune response  
Allo-immune responses to the allograft impede successful kidney transplantation, 
and are characterized by the differentiation of progenitor and intermediate cell 
types to fully differentiated immune cells via a tightly regulated cascade of gene 
expression changes. Recent evidence supports a role for DNA methylation 
changes in orchestrating this process(Figure3).  
Indeed, early on in hematopoiesis, hematopoietic stem cells differentiating into 
the myeloerythroid versus lymphoid lineage achieve markedly different 
methylation patterns(26, 27).  In addition, active demethylation by TET2-
mediated hydroxymethylation is involved in the differentiation of peripheral blood 
monocytes into macrophages and dendritic cells (28-30). Also in the activation of 
macrophages towards the two distinct polarized M1 (representing the ‘classical’ 
activation of macrophages, associated with pro-inflammatory responses) and M2 
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(representing the ‘alternative’ activation, associated with anti-inflammatory 
responses and tissue remodeling) phenotypes, differential DNA methylation is 
involved. Inhibition of DNMT3B is namely able to skew macrophages towards the 
M2 phenotype(31). Interestingly, M2 macrophages are involved in renal 
regeneration by generating mediators that support tubular survival and 
proliferation to restore tubular integrity (32-34). This epigenetic regulation of 
macrophage polarization thus supports the idea of a continuum of macrophage 
phenotypes, rather than fixed polarized phenotypes(35).  
Epigenetics are also involved in the differentiation of naïve CD4+ T cells toward 
effector T helper cells (Th1, Th2, and Th17) or regulatory T (Treg) cells(36). For 
example, the segregation of the Th1 and Th2 cells based on their mutually 
exclusive production of interferon–γ (IFNγ) or interleukin-4 (IL-4), IL-5 and IL-13, 
respectively, is characterized by their corresponding different DNA methylation 
profiles (37). Also for Treg cells that constitutively express Foxp3, a transcription 
factor necessary for its suppressive function, maintaining a stable expression of 
Foxp3 relies upon DNA demethylation of a CpG-rich region within the Foxp3 
locus early in thymic Treg development(38-40). In B cells that are activated in the 
germinal center by antigenic stimulation, global reprogramming of the DNA 
methylome occurs(41). Thereafter, when differentiating into memory B cells or 
plasma cells, the DNA methylome remains mostly unaltered, providing a platform 
for memory B cells to rapidly differentiate into plasma cells upon antigen 
rechallenge(41) . 
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As epigenetic mechanisms determine thus both lineage stability as well as 
lineage plasticity, targeting the epigenome could be promising as a therapeutic 
strategy to prolong kidney transplantation, especially in the era of cell therapy in 
transplantation medicine. For example, Treg cell therapy might improve allograft 
survival but is hampered by the loss of FOXP3 expression during cell expansion 
and transfusion. The inhibition of DNA methylation by DNMT inhibitors could 
potentially promote more stable FOXP3 expression in Tregs(42). In addition, 
epigenetic therapies could be applied to skew macrophages towards the 
regenerative, anti-inflammatory M2 phenotype, and induce less deleterious 
rejection phenotypes(31). The compelling aspects of therapy targeting the 
epigenome are discussed in the last section. 
 
Furthermore, there is an unmet need for monitoring the immune response in 
transplant recipients as sufficiently robust biomarkers to predict long-term 
outcome are currently lacking. In oncology, aberrant DNA methylation patterns 
are used for cancer detection, prognosis and prediction of therapeutic 
responses(43). Only few studies evaluated the role of DNA methylation in 
transplantation medicine. In kidney transplant recipients with subclinical rejection, 
long-term allograft outcome was better when FOXP3+ Treg cells were present in 
allograft biopsies. In these FOXP3+ Treg cells, a locus near FOXP3 was 
unmethylated which distinguishes them from effector T cells, thus serving as a 
protective biomarker(44). Likewise, in hematopoietic stem cell transplantation, 
DNA methylation at genes encoding IFNγ, FASL and IL-10 was associated with 
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the severity of graft-versus-host disease(45). DNA methylation markers can thus 
be used to assess the renal cell composition, and monitor the immune response 
in transplanted patients. Moreover, DNA methylation entails advantages over 
proteins and RNA as a biomarker of immune activation by being more 
accessible, which is discussed in the last section of this minireview.  
 
Finally, besides controlling immune cell differentiation and activation, epigenetic 
regulators are themselves susceptible to inflammation and immune responses. 
For instance, IL-6 is able to elicit epigenetic changes by regulating DNMT 
expression(46). Moreover, several associations between chronic inflammation 
and epigenetic alterations have been observed(47). Although these studies 
suggest an impact of inflammation on epigenetics, much more work needs to be 
done to understand the relevance of this link.   
 
DNA methylation and ischemia-reperfusion injury  
Another factor that adversely impacts kidney transplantation outcome is 
ischemia-reperfusion injury occurring during transplantation. Indeed, prolonged 
cold ischemia is associated with increased risk of delayed graft function 
(DGF)(48), diminished allograft function(49), chronic allograft injury(50) and 
worse allograft survival(51).  
Ischemia and oxidative stress are thought to affect DNA methylation, and several 
underlying mechanisms have been proposed. First, oxidative stress can alter the 
DNA structure, by causing base modifications, deletions, strand breakage, 
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chromosomal rearrangements, and other genetic changes(52). These DNA 
lesions could influence the binding of DNMTs and methyl-binding proteins, 
thereby affecting DNA methylation and influencing transcription(52). Another 
example of oxidative DNA damage is the formation of 8-hydroxy-2-
deoxyguanosine (8-OHdG), whose presence strongly inhibits methylation of 
adjacent cytosines(52). Second, TET enzymes responsible for active 
demethylation use molecular oxygen as co-substrate, suggesting that DNA 
demethylation is arrested during ischemia-reperfusion and gene expression is 
changed accordingly(13). In addition, oxidative stress also affects alpha-
ketoglutarate and Fe(II) levels, which similar to oxygen serve as co-factors for 
TET-mediation demethylation(53, 54). Finally, hypoxia can also directly modulate 
the expression of DNMTs and TET enzymes(55-58). For instance, DNA binding 
consensus sequences for hypoxia-induced transcription factors have been 
identified in the DNMT1 and DNMT3b promoters(57). Taken together, there are 
numerous mechanisms through which ischemia and oxidative stress could 
impact DNA methylation, but a conclusive picture is currently lacking.  
The theoretical association between hypoxia and DNA methylation has been 
explored in different tissues and animal models, albeit only to a very superficial 
extent. In prostate cells, neurons, cardiac and pulmonary fibroblasts, hypoxia or 
ischemia both increase DNA methylation as measured by immunostaining or by 
[3H]methyl incorporation(56, 57, 59, 60). Other small studies examined ischemia-
reperfusion injury in the rodent kidney. One observed reduced 5hmC levels with 
unaltered 5mC levels by immunodot blotting(55). Another focused at only one 
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CpG in the C3 gene promoter, as renal C3 synthesis increases after ischemia-
reperfusion injury and contributes to the injury.  At this locus, demethylation was 
observed after ischemia, with further demethylation after reperfusion(61). In a 
syngeneic rat transplantation model, kidneys characterized by more severe 
chronic injury similarly displayed aberrant methylation of the C3 locus(62). 
Importantly, none of the abovementioned studies investigated DNA methylation 
changes using a genome-wide approach, limiting the breath of conclusions that 
can be drawn. Moreover, except for one(60), none of them directly linked DNA 
methylation changes to gene expression changes.  
 
Thus although the abovementioned studies are of interest and point towards the 
potential importance of epigenetic alteration in ischemia-reperfusion injury, no 
definite conclusions can be drawn from these small, and sometimes conflicting, 
studies. Additional systematic studies are needed to better define the impact of 
ischemia and reperfusion on kidney DNA methylation levels. 
 
DNA methylation and fibrosis  
Similar to wound repair, fibrosis is a process triggered by a specific injury and 
characterized by the deposition of extracellular matrix through activated 
fibroblasts. However, in contrast to wound repair, fibrogenesis can progress even 
after the initiating insult has disappeared(63). DNA methylation could determine 
why different organs respond differently to injury, either by triggering tissue repair 
(cfr. wound healing) or by ongoing scarring (cfr. fibrosis). In nephrology, this is of 
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particular interest: chronic kidney disease (CKD) is characterized by progression 
to tubulointerstitial fibrosis, irrespective of the initiating trigger. However, how the 
kidney progresses from the initial injury to end-stage disease is incompletely 
understood. 
 
Epigenetic changes contribute to fibrosis in several settings, including the heart, 
lungs, liver and skin (64-66). For instance, epigenetic alterations could underlie 
cardiac fibrosis after myocardial infarction, as cardiac fibroblasts exposed to 
hypoxia obtain a pro-fibrotic state that is associated with global DNA 
hypermethylation(57). Administration of a DNMT inhibitor (5-azacytidine) 
moreover reduced cardiac fibrosis and improved systolic and diastolic function in 
a rat model of myocardial infarction(67). In nephrology, epigenetic changes have 
similarly been implicated in fibrosis. In fibroblasts isolated from human fibrotic 
kidneys, hypermethylation of RASAL1 was detected by genome-wide DNA 
methylation profiling(68). RASAL1 inactivates Ras proteins, which induce 
proliferation. Hypermethylation-induced repression of RASAL1 can thus explain 
why fibroblasts are characterized by continuous proliferation. These data were 
validated in murine models of kidney fibrosis, and inhibition of RASAL1 
methylation by 5-azacytidine moreover suppressed kidney fibrosis(68, 69). In 
addition, RASAL1 knockdown lowered RASAL1 expression in nonfibrotic 
fibroblasts to the level of fibrotic fibroblasts, phenocopying the proliferative 
activity and fibrotic potential as observed in fibrotic fibroblasts, suggesting that 
the changes in RASAL1 expression induced by increased methylation are 
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sufficient to promote fibrosis. Moreover, reversal of kidney fibrosis by 
administration of bone morphogenic protein 7 was accompanied by normalization 
of RASAL1 promoter methylation and by de novo RASAL1 hydroxymethylation, 
through increased TET3 expression(69). Finally, further strengthening the 
relevance of these findings, reduced TET3 gene expression was observed in 
publicly available transcriptome data of various kidney diseases(69). 
 
Taken together, these observations reveal a critical role for DNA methylation in 
the pathogenesis of several fibrotic diseases including CKD. In kidney 
transplantation, chronic dysfunction of the allograft and graft failure are often 
characterized by interstitial fibrosis, but DNA methylation changes have hitherto 
not been investigated as a trigger of this process.  
 
 
DNA methylation and kidney function  
The abovementioned studies suggest that DNA methylation changes can be 
found in patients with CKD. Indeed, site-specific DNA methylation changes have 
already been detected in patients with diabetic nephropathy(70), in patients on 
chronic hemodialysis(71) and in patients with CKD in general(72). Moreover, 
DNA methylation changes have been associated with the rate of kidney function 
decline(73). However, others failed to observe an association between global 
DNA methylation and estimated glomerular filtration rate in patients with 
CKD(74). Simple evaluation of global hypo- or hypermethylation can, however, 
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not exclude the possibility that site-specific DNA methylation changes exist. 
Moreover, except for one(72), these studies focused on DNA methylation in 
peripheral blood instead of focusing on the renal tissue itself, thereby limiting the 
extent of conclusions that can be drawn from these data to merely correlative. 
Indeed, it is unclear whether epigenetic changes in CKD directly cause end-stage 
renal disease (ESRD)(72), whether they reflect environmental factors that alter 
DNA methylation in all tissues(75) or whether they are the result of the disease 
on itself(71, 76).  
In line with the latter possibility, it has been demonstrated that uremic toxins, 
which are increased in patients with ESRD and related to the increased 
cardiovascular risk, can induce hypermethylation of Klotho in vitro in human renal 
tubular cells, and in vivo in mice(77). Klotho is a central player in ESRD, with 
Klotho expression being reduced in patients with ESRD, and overexpression of 
Klotho rescuing ESRD in mice. Similarly, the Klotho promoter is hypermethylated 
in renal tissue and in peripheral blood mononuclear cells of patients with CKD, 
with the degree of hypermethylation correlating with the clinical and histological 
severity of CKD(78).  
 
Challenges in epigenetic research and look at the future 
Epigenetics is a novel and booming research field. Many questions unanswered 
today will be tackled tomorrow. When its characteristics become unraveled, the 
future of translational epigenetic research will become evident. Until then, we can 
only speculate that the unique features of epigenetics hold promise for 
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pathogenic insight, biomarker discovery and targeted therapeutics also in 
transplantation.  
The attractiveness of DNA methylation as biomarker lies in its feasibility. It is less 
sensitive to tissue handling compared to RNA or proteins and can even be 
performed on DNA isolated from small amounts of fixed tissue(3). Moreover, 
given the recent interest in donor-derived cell-free DNA as a biomarker in 
transplantation(79), its DNA methylation profile merits further investigation. As for 
every biomarker, a mechanistic understanding of the underlying biology is not 
strictly required, as its sole purpose is to provide a diagnostic or prognostic 
handle. 
On the other hand, when performing epigenetic research to better understand the 
processes associated with transplant failure, compelling aspects of epigenetics 
need to be addressed. First, the region in which DNA methylation changes take 
place determines the effect on gene function, and given the complexity of 
transcription regulation, straightforward effects are not always to be anticipated. 
Therefore, DNA methylation research should take the site-specificity and the 
transcriptional response into account.  
Second, epigenetic research is complicated by cell- and tissue-specific 
methylation patterns. This is particularly relevant when performing DNA 
methylation analyses on tissue biopsies(3). When, for example, one would 
compare DNA methylation of allograft biopsies with acute cellular rejection to 
allograft biopsies without rejection, the presence of inflammatory cells could 
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heavily influence the results. This underlines also why investigating the primary 
organ is superior to studying more accessible secondary derivatives such as 
peripheral blood.  
Third, although cell lineage is the major determinant of DNA methylation 
patterns, they can also be influenced by genetic differences(3, 80). Inter-
individual variation needs thus to be considered and sites with consistent levels 
of methylation in healthy individuals need to be identified before DNA methylation 
profiling can find its way to clinical applications(81). Current efforts to develop 
reference DNA methylation data sets are therefore of utmost importance(81). 
Also genetic variability between individuals can lead to the erroneous 
identification of differentially methylated regions, as single nucleotide 
polymorphisms (SNPs) can disrupt CpG dinucleotides(80) directly influencing 
their methylation. In addition, bisulfite treatment of DNA, necessary for DNA 
methylation analysis, converts unmethylated cytosines to thymines, while 
methylated cytosines are read as cytosines. Therefore, a C to T mismatch SNP 
can be falsely recognized as an unmethylated cytosine(80).  
 
Fourth, besides gender, age and inter-individual differences, other factors 
relevant for the transplantation setting could change DNA methylation, and thus 
confound epigenetic research results. For example, HTK preservation solution 
contains alpha-ketoglutarate, which is an important cofactor for TET activity. DNA 
methylation changes following the use of this preservation solution have not been 
investigated yet. In addition, the epigenetic effects of immunosuppressive drugs, 
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such as corticosteroids(82), need to be established. Moreover, there is currently 
insufficient knowledge on the numerous other factors that could modify the DNA 
methylome, such as nutritional deficiency, inflammation, smoking and obesity. 
 
Fifth, future studies should entail an unbiased approach by investigating the DNA 
methylome in a genome-wide manner to provide a broader as well as a more in-
depth analysis than when only a specific set of genes is studied. Current 
methylation studies moreover fail to discriminate cytosine methylation from 
hydroxymethylation. The development of more specific assays is anticipated to 
provide an even greater sensitivity in detecting relevant epigenetic changes. 
Investigating the role of DNA methylation on allograft outcome could not only aid 
in our understanding of why some kidney transplants fail, and therefore 
contribute to improved diagnostics and risk prediction. Also with respect to 
therapeutics, epigenetic research is promising. DNA methylation is modifiable 
and agents that act on these mechanisms have been developed. Still, finding 
dysregulated DNA methylation in rejection or chronic allograft injury does not 
necessarily imply a therapeutic potential of these agents equally to recent 
advances in haemato-oncology. For example, DNMT inhibitors like 5-
azanucleosides inhibit all DNA methyltransferases. In cancer, the advantages 
could overwhelm its toxicity, but in transplant recipients this toxicity would likely 
be unacceptable. However, with recent developments in (epi-)genome 
engineering technologies, therapy targeted to localized DNA methylation 
changes will no longer be an unattainable dream(83).  
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By addressing these challenges, and by being receptive to discoveries in other 
research fields, epigenetics holds great promise for research in aging-associated, 
allo-immune and ischemia-reperfusion injuries in organ transplantation. 
Continuing this research is crucial, as we still do not succeed in improving long-
term transplant outcome due to incomplete insight in the mechanisms underlying 
and the factors predicting allograft outcome.  
In linking environmental influences to long-lasting cellular phenotypes, epigenetic 
changes underlying the allografts’ fate represent an appealing research domain 
in transplantation. Its unique characteristics, its promise as accessible biomarker 
and its therapeutic potential explain the explosion on epigenetic research in 
medicine. Now it is time for transplantation.   
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Figure legends 
 
Figure 1: DNA methylation of a gene promoter represses gene 
transcription. This DNA methylation occurs at a cytosine followed by guanine 
(CpG dinucleotide). Methylation on this palindrome is mostly symmetrical 
between the top and bottom strand, thereby enabling the propagation of 
methylation states across cell divisions. Cytosine (C) is methylated (5mC) by 
DNA methyltransferases (DNMT). Demethylation is achieved by oxidation of the 
methylgroup to 5-hydroxymethylcytosine (5hmC) through action of the ten-eleven 
translocation methylcytosine dioxygenase (TET) enzymes and the subsequent  
removal of the oxidized base by thymine DNA glycosylase (TDG). TTS, 
transcription start site; DNMT, DNA methyltransferase; TET, ten-eleven 
translocation methylcytosine dioxygenase enzyme.  
 
Figure 2: Schematic overview of the perspectives for DNA methylation 
research in kidney transplantation. 
 
Figure 3: DNA methylation events are involved in immune cell 
development, differentiation and activation. Hematopoietic stem cells achieve 
different methylation patterns when differentiating into the myeloerythroid lineage 
(global hypomethylation) versus lymphoid lineage (global hypermethylation). In 
various immune cells, differentiation into different cell lines and into activated 
differentiated cells is accompanied by changes in methylation patterns, relevant 
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for the function of these cells. In contrast, during the differentiation of effector T 
and B cells into memory cells the effector phase DNA methylation pattern is 
maintained, permitting a strong and quick response to antigen rechallenge.  
 
References 
 
1. Petronis A. Epigenetics as a unifying principle in the aetiology of complex 
traits and diseases. Nature 2010;465(7299):721-727. 
2. Portela A, Esteller M. Epigenetic modifications and human disease. 
Nature biotechnology 2010;28(10):1057-1068. 
3. Schubeler D. Function and information content of DNA methylation. 
Nature 2015;517(7534):321-326. 
4. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 
1986;321(6067):209-213. 
5. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP. A human B cell 
methylome at 100-base pair resolution. Proceedings of the National Academy of 
Sciences of the United States of America 2009;106(3):671-678. 
6. Fazzari MJ, Greally JM. Epigenomics: beyond CpG islands. Nat Rev 
Genet 2004;5(6):446-455. 
7. Hon GC, Rajagopal N, Shen Y, McCleary DF, Yue F, Dang MD et al. 
Epigenetic memory at embryonic enhancers identified in DNA methylation maps 
from adult mouse tissues. Nature genetics 2013;45(10):1198-1206. 
 Page 24 of 37  
8. Deaton AM, Webb S, Kerr AR, Illingworth RS, Guy J, Andrews R et al. 
Cell type-specific DNA methylation at intragenic CpG islands in the immune 
system. Genome Res 2011;21(7):1074-1086. 
9. Illingworth RS, Gruenewald-Schneider U, De Sousa D, Webb S, Merusi C, 
Kerr ARW et al. Inter-individual variability contrasts with regional homogeneity in 
the human brain DNA methylome. Nucleic Acids Research 2015. 
10. Kikuchi R, Yagi S, Kusuhara H, Imai S, Sugiyama Y, Shiota K. Genome-
wide analysis of epigenetic signatures for kidney-specific transporters. Kidney 
international 2010;78(6):569-577. 
11. Marumo T, Yagi S, Kawarazaki W, Nishimoto M, Ayuzawa N, Watanabe A 
et al. Diabetes Induces Aberrant DNA Methylation in the Proximal Tubules of the 
Kidney. Journal of the American Society of Nephrology 2015. 
12. Cedar H, Bergman Y. Linking DNA methylation and histone modification: 
patterns and paradigms. Nat Rev Genet 2009;10(5):295-304. 
13. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. 
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA 
by MLL partner TET1. Science 2009;324(5929):930-935. 
14. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA et al. Tet proteins 
can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. 
Science 2011;333(6047):1300-1303. 
15. Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and 
biological functions. Cell 2014;156(1-2):45-68. 
 Page 25 of 37  
16. Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J et al. Genome-wide 
regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse 
embryonic stem cells. Molecular cell 2011;42(4):451-464. 
17. Bachman M, Uribe-Lewis S, Yang X, Williams M, Murrell A, 
Balasubramanian S. 5-Hydroxymethylcytosine is a predominantly stable DNA 
modification. Nature chemistry 2014;6(12):1049-1055. 
18. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. 
Expanded criteria donors for kidney transplantation. American Journal of 
Transplantation 2003;3:114-125. 
19. Naesens M. Replicative senescence in kidney aging, renal disease, and 
renal transplantation. Discovery medicine 2011;11(56):65-75. 
20. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S et al. 
Genome-wide methylation profiles reveal quantitative views of human aging 
rates. Molecular cell 2013;49(2):359-367. 
21. Jones MJ, Goodman SJ, Kobor MS. DNA methylation and healthy human 
aging. Aging cell 2015:n/a-n/a. 
22. Weidner CI, Ziegler P, Hahn M, Brummendorf TH, Ho AD, Dreger P et al. 
Epigenetic aging upon allogeneic transplantation: the hematopoietic niche does 
not affect age-associated DNA methylation. Leukemia 2014. 
23. Akintola AD, Crislip ZL, Catania JM, Chen G, Zimmer WE, Burghardt RC 
et al. Promoter methylation is associated with the age-dependent loss of N-
cadherin in the rat kidney. American journal of physiology Renal physiology 
2008;294(1):F170-176. 
 Page 26 of 37  
24. Horvath S. DNA methylation age of human tissues and cell types. 
Genome biology 2013;14(10):R115. 
25. Marioni R, Shah S, McRae A, Chen B, Colicino E, Harris S et al. DNA 
methylation age of blood predicts all-cause mortality in later life. Genome biology 
2015;16(1):25. 
26. Bröske A-M, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M 
et al. DNA methylation protects hematopoietic stem cell multipotency from 
myeloerythroid restriction. Nature genetics 2009;41(11):1207-1215. 
27. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P et al. 
Comprehensive methylome map of lineage commitment from haematopoietic 
progenitors. Nature 2010;467(7313):338-342. 
28. Klug M, Heinz S, Gebhard C, Schwarzfischer L, Krause SW, Andreesen R 
et al. Active DNA demethylation in human postmitotic cells correlates with 
activating histone modifications, but not transcription levels. Genome biology 
2010;11(6):R63. 
29. Klug M, Schmidhofer S, Gebhard C, Andreesen R, Rehli M. 5-
Hydroxymethylcytosine is an essential intermediate of active DNA demethylation 
processes in primary human monocytes. Genome biology 2013;14(5):R46. 
30. Zhang X, Ulm A, Somineni HK, Oh S, Weirauch MT, Zhang HX et al. DNA 
methylation dynamics during ex vivo differentiation and maturation of human 
dendritic cells. Epigenetics & chromatin 2014;7:21. 
 Page 27 of 37  
31. Yang X, Wang X, Liu D, Yu L, Xue B, Shi H. Epigenetic regulation of 
macrophage polarization by DNA methyltransferase 3b. Molecular endocrinology 
2014;28(4):565-574. 
32. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS et al. Distinct 
macrophage phenotypes contribute to kidney injury and repair. Journal of the 
American Society of Nephrology : JASN 2011;22(2):317-326. 
33. Schmidt IM, Hall IE, Kale S, Lee S, He CH, Lee Y et al. Chitinase-like 
protein Brp-39/YKL-40 modulates the renal response to ischemic injury and 
predicts delayed allograft function. Journal of the American Society of 
Nephrology : JASN 2013;24(2):309-319. 
34. Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT et al. Macrophage 
Wnt7b is critical for kidney repair and regeneration. Proceedings of the National 
Academy of Sciences of the United States of America 2010;107(9):4194-4199. 
35. Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic 
control of myeloid cell differentiation, identity and function. Nature reviews 
Immunology 2015;15(1):7-17. 
36. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell 
differentiation. Nature Reviews Immunology 2009;9(2):91-105. 
37. Schoenborn JR, Dorschner MO, Sekimata M, Santer DM, Shnyreva M, 
Fitzpatrick DR et al. Comprehensive epigenetic profiling identifies multiple distal 
regulatory elements directing transcription of the gene encoding interferon-
gamma. Nature immunology 2007;8(7):732-742. 
 Page 28 of 37  
38. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP et al. 
Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA 
methylation. The Journal of Immunology 2009;182(1):259-273. 
39. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J et al. 
DNA demethylation in the human FOXP3 locus discriminates regulatory T cells 
from activated FOXP3(+) conventional T cells. European journal of immunology 
2007;37(9):2378-2389. 
40. Toker A, Engelbert D, Garg G, Polansky JK, Floess S, Miyao T et al. 
Active demethylation of the Foxp3 locus leads to the generation of stable 
regulatory T cells within the thymus. Journal of immunology 2013;190(7):3180-
3188. 
41. Lai AY, Mav D, Shah R, Grimm SA, Phadke D, Hatzi K et al. DNA 
methylation profiling in human B cells reveals immune regulatory elements and 
epigenetic plasticity at Alu elements during B-cell activation. Genome Research 
2013;23(12):2030-2041. 
42. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 
expression. Blood 2009;114(18):3727-3735. 
43. Laird PW. The power and the promise of DNA methylation markers. Nat 
Rev Cancer 2003;3(4):253-266. 
44. Bestard O, Cunetti L, Cruzado JM, Lucia M, Valdez R, Olek S et al. 
Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and 
are protective biomarkers for kidney graft outcome. American journal of 
 Page 29 of 37  
transplantation : official journal of the American Society of Transplantation and 
the American Society of Transplant Surgeons 2011;11(10):2162-2172. 
45. Rodriguez RM, Suarez-Alvarez B, Salvanes R, Muro M, Martinez-Camblor 
P, Colado E et al. DNA methylation dynamics in blood after hematopoietic cell 
transplant. PloS one 2013;8(2):e56931. 
46. Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA et al. 
Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter 
methylation. Cancer research 2005;65(11):4673-4682. 
47. Issa J-P. Aging and epigenetic drift: a vicious cycle. The Journal of clinical 
investigation 2014;124(1):24-29. 
48. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed Graft 
Function: Risk Factors and Implications for Renal Allograft Survival1. 
Transplantation 1997;63(7):968-974. 
49. Salahudeen AK, Haider N, May W. Cold ischemia and the reduced long-
term survival of cadaveric renal allografts. Kidney international 2004;65(2):713-
718. 
50. Yilmaz S, McLaughlin K, Paavonen T, Taskinen E, Monroy M, Aavik E et 
al. Clinical Predictors of Renal Allograft Histopathology: A Comparative Study of 
Single-Lesion Histology Versus a Composite, Quantitative Scoring System. 
Transplantation 2007;83(6):671-676  
51. Roodnat J, Mulder P, Van Riemsdijk I, IJzermans J, Van Gelder T, 
Weimar W. Ischemia times and donor serum creatinine in relation to renal graft 
failure. Transplantation 2003;75(6):799-804. 
 Page 30 of 37  
52. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative 
stress, DNA methylation and carcinogenesis. Cancer letters 2008;266(1):6-11. 
53. Chia N, Wang L, Lu X, Senut MC, Brenner C, Ruden DM. Hypothesis: 
environmental regulation of 5-hydroxymethylcytosine by oxidative stress. 
Epigenetics 2011;6(7):853-856. 
54. Niu Y, DesMarais TL, Tong Z, Yao Y, Costa M. Oxidative stress alters 
global histone modification and DNA methylation. Free radical biology & 
medicine 2015;82:22-28. 
55. Huang N, Tan L, Xue Z, Cang J, Wang H. Reduction of DNA 
hydroxymethylation in the mouse kidney insulted by ischemia reperfusion. 
Biochem Biophys Res Commun 2012;422(4):697-702. 
56. Watson JA, Watson CJ, McCrohan AM, Woodfine K, Tosetto M, McDaid J 
et al. Generation of an epigenetic signature by chronic hypoxia in prostate cells. 
Hum Mol Genet 2009;18(19):3594-3604. 
57. Watson CJ, Collier P, Tea I, Neary R, Watson JA, Robinson C et al. 
Hypoxia-induced epigenetic modifications are associated with cardiac tissue 
fibrosis and the development of a myofibroblast-like phenotype. Hum Mol Genet 
2014;23(8):2176-2188. 
58. Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y et 
al. TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in 
Neuroblastoma. Cell reports 2014;7(5):1343-1352. 
 Page 31 of 37  
59. Endres M, Meisel A, Biniszkiewicz D, Namura S, Prass K, Ruscher K et al. 
DNA methyltransferase contributes to delayed ischemic brain injury. The Journal 
of Neuroscience 2000;20(9):3175-3181. 
60. Robinson CM, Neary R, Levendale A, Watson CJ, Baugh JA. Hypoxia-
induced DNA hypermethylation in human pulmonary fibroblasts is associated 
with Thy-1 promoter methylation and the development of a pro-fibrotic 
phenotype. Respiratory research 2012;13:74. 
61. Pratt JR, Parker MD, Affleck LJ, Corps C, Hostert L, Michalak E et al. 
Ischemic epigenetics and the transplanted kidney. Transplantation proceedings 
2006;38(10):3344-3346. 
62. Parker MD, Chambers PA, Lodge JP, Pratt JR. Ischemia- reperfusion 
injury and its influence on the epigenetic modification of the donor kidney 
genome. Transplantation 2008;86(12):1818-1823. 
63. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing 
interstitial fibrosis. Journal of nephrology 2000;13 Suppl 3:S111-120. 
64. Hagood JS. Beyond the genome: epigenetic mechanisms in lung 
remodeling. Physiology 2014;29(3):177-185. 
65. Bian EB, Huang C, Wang H, Wu BM, Zhang L, Lv XW et al. DNA 
methylation: new therapeutic implications for hepatic fibrosis. Cellular signalling 
2013;25(1):355-358. 
66. Altorok N, Almeshal N, Wang Y, Kahaleh B. Epigenetics, the holy grail in 
the pathogenesis of systemic sclerosis. Rheumatology 2014. 
 Page 32 of 37  
67. Kim YS, Kang WS, Kwon JS, Hong MH, Jeong HY, Jeong HC et al. 
Protective role of 5-azacytidine on myocardial infarction is associated with 
modulation of macrophage phenotype and inhibition of fibrosis. Journal of cellular 
and molecular medicine 2014;18(6):1018-1027. 
68. Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant 
DJ et al. Methylation determines fibroblast activation and fibrogenesis in the 
kidney. Nature medicine 2010;16(5):544-550. 
69. Tampe B, Tampe D, Muller CA, Sugimoto H, LeBleu V, Xu X et al. Tet3-
mediated hydroxymethylation of epigenetically silenced genes contributes to 
bone morphogenic protein 7-induced reversal of kidney fibrosis. Journal of the 
American Society of Nephrology : JASN 2014;25(5):905-912. 
70. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA. 
Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 
diabetes mellitus. BMC medical genomics 2010;3(1):33. 
71. Zawada AM, Rogacev KS, Hummel B, Grün OS, Friedrich A, Rotter B et 
al. SuperTAG methylation-specific digital karyotyping (SMSDK) reveals uremia 
induced epigenetic dysregulation of atherosclerosis-related genes. Circulation: 
Cardiovascular Genetics 2012:CIRCGENETICS. 112.963207. 
72. Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY et al. 
Cytosine methylation changes in enhancer regions of core pro-fibrotic genes 
characterize kidney fibrosis development. Genome biology 2013;14(10):R108. 
73. Wing MR, Devaney JM, Joffe MM, Xie D, Feldman HI, Dominic EA et al. 
DNA methylation profile associated with rapid decline in kidney function: findings 
 Page 33 of 37  
from the CRIC study. Nephrology, dialysis, transplantation : official publication of 
the European Dialysis and Transplant Association - European Renal Association 
2014;29(4):864-872. 
74. Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B 
et al. Impact of inflammation on epigenetic DNA methylation – a novel risk factor 
for cardiovascular disease? Journal of Internal Medicine 2007;261(5):488-499. 
75. Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J et al. DNA 
methylation profiling identifies epigenetic differences between diabetes patients 
with ESRD and diabetes patients without nephropathy. Epigenetics 2011;6(1):20-
28. 
76. Dwivedi RS, Herman JG, McCaffrey TA, Raj DS. Beyond genetics: 
epigenetic code in chronic kidney disease. Kidney international 2011;79(1):23-
32. 
77. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-
bound uremic toxins is associated with increased DNA methyltransferase 
expression and DNA hypermethylation. Kidney international 2012;81(7):640-650. 
78. Chen J, Zhang X, Zhang H, Lin J, Zhang C, Wu Q et al. Elevated Klotho 
promoter methylation is associated with severity of chronic kidney disease. PloS 
one 2013;8(11):e79856. 
79. Gielis EM, Ledeganck KJ, De Winter BY, Del Favero J, Bosmans JL, 
Claas FHJ et al. Cell-Free DNA: An Upcoming Biomarker in Transplantation. 
American Journal of Transplantation 2015:n/a-n/a. 
 Page 34 of 37  
80. Gertz J, Varley KE, Reddy TE, Bowling KM, Pauli F, Parker SL et al. 
Analysis of DNA methylation in a three-generation family reveals widespread 
genetic influence on epigenetic regulation. PLoS genetics 2011;7(8):e1002228. 
81. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications 
and challenges. Nat Rev Genet 2012;13(10):679-692. 
82. Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 
2: Mechanisms. Nat Rev Endocrinol 2014;10(7):403-411. 
83. Falahi F, Sgro A, Blancafort P. Epigenome engineering in cancer: fairytale 
or a realistic path to the clinic? Front Oncol 2015;5:22. 
 
 
 
 Page 35 of 37  
 
Figure 1: DNA methylation of a gene promoter represses gene 
transcription. This DNA methylation occurs at a cytosine followed by guanine 
(CpG dinucleotide). Methylation on this palindrome is mostly symmetrical 
between the top and bottom strand, thereby enabling the propagation of 
methylation states across cell divisions. Cytosine (C) is methylated (5mC) by 
DNA methyltransferases (DNMT). Demethylation is achieved by oxidation of the 
methylgroup to 5-hydroxymethylcytosine (5hmC) through action of the ten-eleven 
translocation methylcytosine dioxygenase (TET) enzymes and the subsequent 
removal of the oxidized base by thymine DNA glycosylase (TDG). TTS, 
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transcription start site; DNMT, DNA methyltransferase; TET, ten-eleven 
translocation methylcytosine dioxygenase enzyme.  
 
Figure 2: Schematic overview of the perspectives for DNA methylation 
research in kidney transplantation 
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Figure 3. DNA methylation events are involved in immune cell 
development, differentiation and activation. Hematopoietic stem cells achieve 
different methylation patterns when differentiating into the myeloerythroid lineage 
(global hypomethylation) versus lymphoid lineage (global hypermethylation). In 
various immune cells, differentiation into different cell lines and into activated 
differentiated cells is accompanied by changes in methylation patterns, relevant 
for the function of these cells. In contrast, during the differentiation of effector T 
and B cells into memory cells the effector phase DNA methylation pattern is 
maintained, permitting a strong and quick response to antigen rechallenge.  
 
